Purpose: Ranitidine hydrochloride (HCl) remains an important medication for treating acid-peptic ailments such as Gastroesophageal reflux disease (GERD). The main objective of this Post Marketing Surveillance (PMS) cl...Purpose: Ranitidine hydrochloride (HCl) remains an important medication for treating acid-peptic ailments such as Gastroesophageal reflux disease (GERD). The main objective of this Post Marketing Surveillance (PMS) clinical study was to test the efficacy and safety of Ranitidine HCl in Indian patients suffering from GERD. Patients and Methods: Data of 2446 patients (1307 males;1121 females) from 21 centers across India were analyzed. Patients received either of the three treatments: Ranitidine HCl 150 mg twice a day (BID) (ARM-A), Ranitidine HCl 300 mg once daily (OD) or BID (ARM-B), and Ranitidine HCl 300 mg OD (ARM-C). Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) score and Heartburn Severity score were used to assess the drug’s efficacy. The adverse events reported by patients or investigators were analyzed to assess the safety profile of Ranitidine. Results: Of the 2446 subjects screened, 2428 were enrolled. There was a significant reduction in GSAS scores from baseline to the end of the study visit in all three ARMs. The GSAS scores reduced from 2.02 to 0.23 in ARM-A, 2.01 to 0.24 in ARM-B, and 2.07 to 0.26 in ARM-C patients. In ARM A, 72.82% had 24 hours heartburn-free days, and 66.89% had 7 consecutive heartburn-free days, which was more significant than the other two ARMs. 128 (5.27%) patients reported ADRs due to Ranitidine HCl at different doses. The most frequently reported ADR was constipation (17.18%), followed by oliguria (14.06%), cold (13.28%), and dysuria (12.5%). Of 128 ADRs, 113 (88.28%) were mild, and only 11 (8.59%) ADRs were related to the study drug. No severe ADRs were reported during the study. Conclusion: Ranitidine HCl 150/300 mg tablet was found to be an effective and safe H2-receptor antagonist for treating GERD in Indian Patients.展开更多
目的:建立盐酸雷尼替丁胶囊溶出度的测定方法。方法:采用HPLC法测定盐酸雷尼替丁胶囊溶出度,色谱柱为JADE PAK C_(18)(4.6 mm×250 mm, 5μm),流动相为0.1%甲酸的乙腈溶液-5 mmol·L^(-1)甲酸铵溶液(10∶90),柱温为35℃,波长为3...目的:建立盐酸雷尼替丁胶囊溶出度的测定方法。方法:采用HPLC法测定盐酸雷尼替丁胶囊溶出度,色谱柱为JADE PAK C_(18)(4.6 mm×250 mm, 5μm),流动相为0.1%甲酸的乙腈溶液-5 mmol·L^(-1)甲酸铵溶液(10∶90),柱温为35℃,波长为314 nm。结果:雷尼替丁在27.189~203.91μg·mL^(-1)范围内,线性关系良好(r=0.999 8),平均回收率为100.3%,RSD为0.6%(n=9)。测定13家企业158批次样品,其中56批次与参比制剂溶出行为不一致。结论:该方法经方法学验证,可用于盐酸雷尼替丁胶囊的溶出度测定。展开更多
文摘Purpose: Ranitidine hydrochloride (HCl) remains an important medication for treating acid-peptic ailments such as Gastroesophageal reflux disease (GERD). The main objective of this Post Marketing Surveillance (PMS) clinical study was to test the efficacy and safety of Ranitidine HCl in Indian patients suffering from GERD. Patients and Methods: Data of 2446 patients (1307 males;1121 females) from 21 centers across India were analyzed. Patients received either of the three treatments: Ranitidine HCl 150 mg twice a day (BID) (ARM-A), Ranitidine HCl 300 mg once daily (OD) or BID (ARM-B), and Ranitidine HCl 300 mg OD (ARM-C). Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) score and Heartburn Severity score were used to assess the drug’s efficacy. The adverse events reported by patients or investigators were analyzed to assess the safety profile of Ranitidine. Results: Of the 2446 subjects screened, 2428 were enrolled. There was a significant reduction in GSAS scores from baseline to the end of the study visit in all three ARMs. The GSAS scores reduced from 2.02 to 0.23 in ARM-A, 2.01 to 0.24 in ARM-B, and 2.07 to 0.26 in ARM-C patients. In ARM A, 72.82% had 24 hours heartburn-free days, and 66.89% had 7 consecutive heartburn-free days, which was more significant than the other two ARMs. 128 (5.27%) patients reported ADRs due to Ranitidine HCl at different doses. The most frequently reported ADR was constipation (17.18%), followed by oliguria (14.06%), cold (13.28%), and dysuria (12.5%). Of 128 ADRs, 113 (88.28%) were mild, and only 11 (8.59%) ADRs were related to the study drug. No severe ADRs were reported during the study. Conclusion: Ranitidine HCl 150/300 mg tablet was found to be an effective and safe H2-receptor antagonist for treating GERD in Indian Patients.
文摘目的:建立盐酸雷尼替丁胶囊溶出度的测定方法。方法:采用HPLC法测定盐酸雷尼替丁胶囊溶出度,色谱柱为JADE PAK C_(18)(4.6 mm×250 mm, 5μm),流动相为0.1%甲酸的乙腈溶液-5 mmol·L^(-1)甲酸铵溶液(10∶90),柱温为35℃,波长为314 nm。结果:雷尼替丁在27.189~203.91μg·mL^(-1)范围内,线性关系良好(r=0.999 8),平均回收率为100.3%,RSD为0.6%(n=9)。测定13家企业158批次样品,其中56批次与参比制剂溶出行为不一致。结论:该方法经方法学验证,可用于盐酸雷尼替丁胶囊的溶出度测定。
